Summary：Exciting HeorModel 0.7.3 Release Unveils Powerful New Features for Users **Introduction** The late

Exciting HeorModel 0.7.3 Release Unveils Powerful New Features for Users

**Introduction**
The latest iteration of HeorModel, version 0.7.3, has arrived, promising to sharpen the toolkit of analysts engaged in health economic evaluation and health technology assessment (HTA). Built around decision‑analytic modeling, this update refines how probabilistic parameters, cohort and individual‑level simulation engines, cost‑effectiveness analysis, and value‑of‑information (VOI) calculations are handled. Stakeholders ranging from academic researchers to pharmaceutical market access teams can expect a more seamless workflow and deeper insight into the uncertainty that surrounds therapeutic value propositions.

**Key Developments**
HeorModel 0.7.3 introduces three core enhancements. First, the probabilistic parameter module now supports correlated input distributions, allowing users to capture realistic joint uncertainty without resorting to ad‑hoc workarounds. Second, the simulation engine has been split into two distinct modes: a fast cohort‑level solver for rapid scenario testing and a granular individual‑level simulator that tracks patient‑level heterogeneity, enabling more nuanced subgroup analyses. Third, the VOI framework has been expanded to include expected value of perfect information (EVPI) and expected value of partial perfect information (EVPPI) calculations directly within the model interface, eliminating the need for external scripting. Performance benchmarks show a 22 % reduction in runtime for large‑scale microsimulations, while the updated GUI offers drag‑and‑drop variable mapping and real‑time diagnostic plots.

**Industry Analysis**
The release arrives at a moment when HTA bodies worldwide are tightening evidentiary standards and demanding transparent, reproducible economic models. By integrating correlated probabilistic inputs and offering dual‑speed simulation, HeorModel 0.7.3 addresses two pain points frequently cited in recent HTA guidance documents: the difficulty of representing